Format

Send to

Choose Destination
Curr Opin Pharmacol. 2001 Oct;1(5):451-8.

Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.

Author information

1
Antimicrobials and Host Defense, GlaxoSmithKline, Collegeville, PA 19426-0989, USA. linda_a_miller@gsk.com

Abstract

Combinations of beta-lactams and beta-lactamase inhibitors have become one of the most successful antibacterial strategies in our global battle against bacterial infections. The success of these agents is particularly emphasized by the continued efficacy of Augmenting (amoxicillin and clavulanate) after nearly 20 years of clinical use. The clinical situation now dictates that second-generation beta-lactamase inhibitors capable of encompassing both class A and class C beta-lactamases would combat emerging resistance and provide a vital addition to our armory of hospital antibiotics. This realization has generated a renewed interest in beta-lactamase inhibitors and improved the prospects for the delivery of such agents in the future.

PMID:
11764769
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center